Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine Approved in Canada for Adults Aged 50-59 at Increased Risk
Ahead of peak RSV season, Canadians aged 50-59 years at increased risk for RSV disease can now better protect themselves against this vaccine-preventable disease Adults aged 50 and older with… Read More



